Sunshine Biopharma (SBFM) Net Margin (2015 - 2026)

Sunshine Biopharma has reported Net Margin for 9 years, with the latest figure at 15.38% in Q1 2026.

• For the quarter ending Q1 2026, Net Margin fell 212.0% year-over-year to 15.38%; the trailing twelve-month figure through Mar 2026 stood at 17.02% (up 41.0% YoY), and the FY2025 full-year result was 16.46%, down 174.0% from the prior year.
• Net Margin for Q1 2026 stood at 15.38%, up from 24.96% in the prior quarter.
• The five-year high for Net Margin was 3.14% in Q3 2025, with the low at 1097.09% in Q3 2022.
• Historically, Net Margin has averaged 193.72% across 5 years, with a median of 19.11% in 2024.
• The largest YoY upside for Net Margin was 1443245 bps in 2022 against a maximum downside of 138054 bps in 2022.
• Sunshine Biopharma's Net Margin stood at 596.78% in 2022, then surged by 97 bps to 16.28% in 2023, then tumbled by 38 bps to 22.49% in 2024, then fell by 11 bps to 24.96% in 2025, then jumped by 38 bps to 15.38% in 2026.
• The last three Net Margin figures came in at 15.38% (Q1 2026), 24.96% (Q4 2025), and 3.14% (Q3 2025), per Business Quant data.